Table 5. Treatment response in 327 NSCLC patients treated with first-line platinum-based chemotherapy.

Treatment response	DBIL		P
	Low DBIL (n = 148)	High DBIL (n = 27)
CR	11 (7.43)	3 (11.11)	0.045
PR	43 (29.05)	14 (51.85)
SD	59 (39.86)	4 (14.81)
PD	35 (23.65)	6 (22.22)
Responder (CR and PR)	54 (36.49)	17 (62.96)	0.010
Non-responder (SD and PD)	94 (63.51)	10 (37.03)

CR complete response, PR partial response, SD stable disease, PD progressive disease.

All data were analyzed using χ² test.